CENI, COSTANZA
 Distribuzione geografica
Continente #
NA - Nord America 133
EU - Europa 53
AS - Asia 27
Totale 213
Nazione #
US - Stati Uniti d'America 132
IT - Italia 18
CN - Cina 12
SE - Svezia 12
IE - Irlanda 11
HK - Hong Kong 8
RU - Federazione Russa 8
JO - Giordania 3
DE - Germania 2
IN - India 2
SG - Singapore 2
CA - Canada 1
FI - Finlandia 1
GB - Regno Unito 1
Totale 213
Città #
Fairfield 17
Ashburn 15
Chandler 11
Dublin 11
Seattle 9
Moscow 8
Wilmington 8
Houston 7
Woodbridge 7
Altamura 6
Florence 6
Hong Kong 6
Lawrence 6
Cambridge 5
San Diego 4
Ann Arbor 3
Beijing 3
Princeton 3
Redwood City 3
Boardman 2
Camerino 2
Medford 2
Nanjing 2
New York 2
Norwalk 2
Pontassieve 2
Shanghai 2
Singapore 2
Tianjin 2
West Jordan 2
Boston 1
Buffalo 1
Chengdu 1
Gavirate 1
Guangzhou 1
Islington 1
Lappeenranta 1
Los Angeles 1
Nagold 1
Pune 1
Toronto 1
Wuhan 1
Totale 172
Nome #
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 89
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 64
Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents 63
Identification of GM1-Ganglioside Secondary Accumulation in Fibroblasts from Neuropathic Gaucher Patients and Effect of a Trivalent Trihydroxypiperidine Iminosugar Compound on Its Storage Reduction 11
Totale 227
Categoria #
all - tutte 968
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 968


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202043 0 0 0 3 5 4 6 4 5 11 3 2
2020/202146 10 3 1 4 3 7 2 6 2 4 4 0
2021/202227 2 2 4 0 4 0 2 1 1 4 2 5
2022/202367 7 17 7 2 2 8 9 4 5 0 5 1
2023/202442 1 3 3 1 4 4 1 11 2 9 2 1
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 227